Ambiq Micro Chief Technology Officer Sold Shares Worth Over $604K

Jefferies initiated coverage on Ambiq Micro (NYSE: AMBQ) with a buy rating and $90 price target, citing its AI edge computing potential. The company's SPOT architecture offers power advantages for edge devices. Ambiq Micro reported 89.7% revenue growth in Q2, with full-year sales outlook raised to $135 million. Several analysts revised earnings upwards, and multiple firms increased price targets.

Ambiq Micro reported Q2 2026 results and said revenue rose 90% year over year, driven by stronger Edge AI demand and growth across Apollo II and Apollo IV, with Apollo V more than doubling on a new large customer ramp. Management projected Q3 net sales up ~100% YoY and 2026 revenue about $135M, despite supply constraints limiting shipments. Gross margin expected to improve modestly in 2026.

Ambiq Micro reported Q2 net loss of $7.1 million, or $0.32 per share, narrowing from $8.5 million a year earlier, as revenue rose 89.7% on stronger demand for ultra-low power edge AI chips. Q2 gross profit more than doubled to $15.3 million and gross margin rose to 45%. H1 net loss was $17.3 million. Cash was $366.8 million after a June follow-on raising $167.9 million net proceeds.

Ambiq Micro (AMBQ) reported Q2 2026 net sales of $33.9 million, up 89.7% year over year, citing accelerating edge AI demand. Non-GAAP gross margin was 47.2%. Full-year net sales guidance is about $135 million, with Q3 revenue outlook of $36 million to $37 million. Management cited supply constraints limiting order fulfillment and said cash was $366.8 million as of June 30, 2026.

Ambiq Micro, Inc. (AMBQ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ambiq Reports Second Quarter 2026 Financial Results Delivered record quarterly net sales, increasing approximately 90% year-over-year, driven by strong demand for edge AI solutions Gross profit more than doubled year-over-year on higher net sales and margin expansion Expect third

Stryker Corporation has appointed Spencer Stiles as its next CEO, effective January 1, 2027. Current CEO Kevin Lobo will become executive chair. The company also announced a $400 million investment in CMR Surgical to support its Versius surgical robotics portfolio. Stryker reported Q2 2026 revenue of $6.59 billion, a 9.40% increase year-over-year, with adjusted earnings per share of $3.69, exceeding estimates.